{"id":"W2590983141","doi":"10.1182/blood.v118.21.811.811","title":"Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Bortezomib; Internal medicine; Multiple myeloma; Clinical endpoint; Panobinostat; Oncology; Progression-free survival; Phases of clinical research; Clinical trial; Surrogate endpoint; Gastroenterology; Adverse effect; Chemotherapy; Histone deacetylase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002530673,0.001938058,0.002315233,0.0004328957,0.0003203691,0.0014965,0.000884619,0.001116372,0.004077334],"category_scores_gemma":[0.001552841,0.0005901547,0.001836898,0.0007442927,0.00108026,0.001241136,0.000547946,0.0026187,0.0007760437],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001086011,"about_ca_system_score_gemma":0.001311692,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001018977,"about_ca_topic_score_gemma":0.002471853,"domain_scores_codex":[0.9991721,0.0005045139,0.00004941309,0.000128293,0.00005770687,0.00008803108],"domain_scores_gemma":[0.9992051,0.0001585526,0.0001786408,0.00005012362,0.00005078121,0.0003569148],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9435362,0.006933483,0.002632949,0.0008981419,0.002163563,0.00009535508,0.0001335569,0.0005034201,0.006470333,0.0001561597,0.00215783,0.03431903],"study_design_scores_gemma":[0.9336475,0.06142778,0.002809321,0.00003734466,0.0005330968,0.00005163826,0.00003053633,0.0002397328,0.0003201674,0.0001272865,0.0007593033,0.00001616974],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9843833,0.006423412,0.0003755991,0.001223265,0.0003823422,0.002437209,0.001691697,0.0001196252,0.002963672],"genre_scores_gemma":[0.981845,0.004802628,0.001515945,0.001904779,0.0004828281,0.00325746,0.003153501,0.00005147981,0.002986459],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004077334,"threshold_uncertainty_score":0.01364011,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01980632799239791,"score_gpt":0.2789102579825956,"score_spread":0.2591039299901977,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}